More Biotech Ph.D.'s Opting To Take Postdocs In Industry

Better pay and richer research environments in the business sector lure young science grads away from academic labs Two years ago, when Thomas Malvar was finishing his doctorate in molecular immunology, he came to a major career crossroads. Should he go the traditional route and do his postdoctoral training in a university? Or should he follow a more adventurous path and do his postdoc in industry--a road that some of his professors warned was a professional dead end? Like a small but growin

Written byJean Wallace
| 11 min read

Register for free to listen to this article
Listen with Speechify
0:00
11:00
Share

Like a small but growing number of other life scientists with newly acquired Ph.D.'s, Malvar chose industry. He's doing his postdoc at Ecogen Inc., an agricultural biotech firm in Langhorne, Pa. There, he's using recombinant DNA technology to study the lethal effects of microbial toxins on beetles and caterpillars. And he says he made the right decision.

"Coming out of academia, you're kind of biased against industry," he says. "But I no longer have that negative view.

"I've found this to be a very positive experience. The company has a very academic atmosphere. They recognize what the postdoctoral position is all about--that you have to be able to publish and develop your career."

Doing a postdoc in industry can be a stepping stone to a first- rate career in basic research--but it can also be a stumbling block if you're not careful, industry experts advise. "At the best companies, your ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies